Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration

EBioMedicine

Volumn 14, Issue , 2016, Pages 168-175

  Constable, Ian J ^a,b,c   Pierce, Cora M ^a   Lai, Chooi May ^a,c   Magno, Aaron L ^a   Degli Esposti, Mariapia A ^a,c   French, Martyn A ^d   McAllister, Ian L ^a,b,c   Butler, Steve ^e   Barone, Samuel B ^e   Schwartz, Steven D ^f   Blumenkranz, Mark S ^g   Rakoczy, Elizabeth P ^a,c  

^a LIONS EYE INSTITUTE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Avalanche Biotechnologies   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

AAV.sFLT 1; Clinical trial; Gene therapy; Wet age related macular degeneration

Indexed keywords

GENE THERAPY AGENT; PARVOVIRUS VECTOR; RANIBIZUMAB; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VIRUS DNA; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADENO ASSOCIATED VIRUS 2; ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG SAFETY; ENDOPHTHALMITIS; ENZYME LINKED IMMUNOSPOT ASSAY; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA HEMORRHAGE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUG ADMINISTRATION; VERY ELDERLY; VIRAL GENE THERAPY; VISUAL IMPAIRMENT; VITRECTOMY; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CASE CONTROL STUDY; CLINICAL TRIAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; RETINA; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; RANIBIZUMAB; RETINA; TISSUE DISTRIBUTION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; WET MACULAR DEGENERATION;

EID: 85003977057     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.11.016     Document Type: Article

References (31)

1. Bennett, J., Ashtari, M., Wellman, J., Marshall, K.A., Cyckowski, L.L., Chung, D.C., Mccague, S., Pierce, E.A., Chen, Y., Bennicelli, J.L., Zhu, X., Ying, G.S., Sun, J., Wright, J.F., Auricchio, A., Simonelli, F., Shindler, K.S., Mingozzi, F., High, K.A., Maguire, A.M., AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 4, 2012, 120ra15.
2. Blankenship, G.W., Machemer, R., Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 92 (1985), 503–506.
3. Bouck, N., PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. 8 (2002), 330–334.
4. Congdon, N., O'Colmain, B., Klaver, C.C., Klein, R., Munoz, B., Friedman, D.S., Kempen, J., Taylor, H.R., Mitchell, P., Eye Diseases Prevalence Research, G., Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122 (2004), 477–485.
5. CATT Research Group, Martin, D.F., Maguire, M.G., Ying, G.S., Grunwald, J.E., Fine, S.L., Jaffe, G.J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364 (2011), 1897–1908.
6. Heier, J.S., Brown, D.M., Chong, V., Korobelnik, J.F., Kaiser, P.K., Nguyen, Q.D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Groetzbach, G., Sommerauer, B., Sandbrink, R., Simader, C., Schmidt-Erfurth, U., View & Groups, V. S, Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
7. Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J.P., Daly, T., Wiegand, S.J., Yancopoulos, G.D., Rudge, J.S., VEGF-trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 11393–11398.
8. IVAN Study Investigators, Chakravarthy, U., Harding, S.P., Rogers, C.A., Downes, S.M., Lotery, A.J., Wordsworth, S., Reeves, B.C., Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119 (2012), 1399–1411.
9. Kaiser, P.K., Brown, D.M., Zhang, K., Hudson, H.L., Holz, F.G., Shapiro, H., Schneider, S., Acharya, N.R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J. Ophthalmol. 144 (2007), 850–857.
10. Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10705–10709.
11. Kliffen, M., Sharma, H.S., Mooy, C.M., Kerkvliet, S., De Jong, P.T., Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81 (1997), 154–162.
12. Lai, C.M., Brankov, M., Zaknich, T., Lai, Y.K., Shen, W.Y., Constable, I.J., Kovesdi, I., Rakoczy, P.E., Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12 (2001), 1299–1310.
13. Lai, C.M., Estcourt, M.J., Himbeck, R.P., Lee, S.Y., Yew-San Yeo, I., Luu, C., Loh, B.K., Lee, M.W., Barathi, A., Villano, J., Ang, C.L., Van Der Most, R.G., Constable, I.J., Dismuke, D., Samulski, R.J., Degli-Esposti, M.A., Rakoczy, E.P., Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 19 (2012), 999–1009.
14. Lai, C.M., Estcourt, M.J., Wikstrom, M., Himbeck, R.P., Barnett, N.L., Brankov, M., Tee, L.B., Dunlop, S.A., Degli-Esposti, M.A., Rakoczy, E.P., rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest. Ophthalmol. Vis. Sci. 50 (2009), 4279–4287.
15. Lai, C.M., Shen, W.Y., Brankov, M., Lai, Y.K., Barnett, N.L., Lee, S.Y., Yeo, I.Y., Mathur, R., Ho, J.E., Pineda, P., Barathi, A., Ang, C.L., Constable, I.J., Rakoczy, E.P., Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. 12 (2005), 659–668.
16. Lai, Y.K., Sharma, S., Lai, C.M., Brankov, M., Constable, I.J., Rakoczy, P.E., Virus-mediated secretion gene therapy – a potential treatment for ocular neovascularization. Adv. Exp. Med. Biol. 533 (2003), 447–453.
17. Lai, Y.K., Shen, W.Y., Brankov, M., Lai, C.M., Constable, I.J., Rakoczy, P.E., Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9 (2002), 804–813.
18. Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy, S.R., Michels, S., Feuer, W., Davis, J.L., Flynn, H.W. Jr., Esquiabro, M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J. Ophthalmol. 148 (2009), 43–58, e1.
19. Li, Q., Miller, R., Han, P.Y., Pang, J., Dinculescu, A., Chiodo, V., Hauswirth, W.W., Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14 (2008), 1760–1769.
20. Luo, L., Uehara, H., Zhang, X., Das, S.K., Olsen, T., Holt, D., Simonis, J.M., Jackman, K., Singh, N., Miya, T.R., Huang, W., Ahmed, F., Bastos-Carvalho, A., Le, Y.Z., Mamalis, C., Chiodo, V.A., Hauswirth, W.W., Baffi, J., Lacal, P.M., Orecchia, A., Ferrara, N., Gao, G., Young-Hee, K., Fu, Y., Owen, L., Albuquerque, R., Baehr, W., Thomas, K., Li, D.Y., Chalam, K.V., Shibuya, M., Grisanti, S., Wilson, D.J., Ambati, J., Ambati, B.K., Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife, 2, 2013, e00324.
21. Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., Rossi, S., Lyubarsky, A., Arruda, V.R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'osso, L., Hertle, R., Ma, J.X., Redmond, T.M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K.S., Maguire, M.G., Wright, J.F., Volpe, N.J., Mcdonnell, J.W., Auricchio, A., High, K.A., Bennett, J., Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2240–2248.
22. Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360.
23. Ohno-Matsui, K., Morita, I., Tombran-Tink, J., Mrazek, D., Onodera, M., Uetama, T., Hayano, M., Murota, S.I., Mochizuki, M., Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell. Physiol. 189 (2001), 323–333.
24. Pierce, E.A., Bennett, J., The status of RPE65 Gene therapy trials: safety and efficacy. Cold Spring Harb. Perspect. Med., 5, 2015, a017285.
25. Rakoczy, E.P., Lai, C.M., Magno, A.L., Wikstrom, M.E., French, M.A., Pierce, C.M., Schwartz, S.D., Blumenkranz, M.S., Chalberg, T.W., Degli-Esposti, M.A., Constable, I.J., Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, 2015.
26. Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y., Group, M.S., Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006), 1419–1431.
27. Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.F., Brown, D.M., Chong, V., Nguyen, Q.D., Ho, A.C., Ogura, Y., Simader, C., Jaffe, G.J., Slakter, J.S., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Sowade, O., Zeitz, O., Norenberg, C., Sandbrink, R., Heier, J.S., Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
28. Simonelli, F., Maguire, A.M., Testa, F., Pierce, E.A., Mingozzi, F., Bennicelli, J.L., Rossi, S., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Redmond, T.M., Zhu, X., Shindler, K.S., Ying, G.S., Ziviello, C., Acerra, C., Wright, J.F., Mcdonnell, J.W., High, K.A., Bennett, J., Auricchio, A., Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18 (2010), 643–650.
29. Testa, F., Maguire, A.M., Rossi, S., Pierce, E.A., Melillo, P., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Acerra, C., Wright, J.F., Wellman, J., High, K.A., Auricchio, A., Bennett, J., Simonelli, F., Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
30. Uehara, H., Mamalis, C., Mcfadden, M., Taggart, M., Stagg, B., Passi, S., Earle, P., Chakravarthy, U., Hogg, R.E., Ambati, B.K., The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration. Am J. Ophthalmol. 159:92–100 (2015), e1–e2.
31. Vasireddy, V., Mills, J.A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A.D., Alexandrov, K., Zhou, S., Maguire, A.M., Chung, D.C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J.L., French, D.L., Bennett, J., AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One, 8, 2013, e61396.